olivLaw · US equity research
NewGenIvf Group Ltd NIVF
Services-Misc Health & Allied Services, NEC · SIC 8090 · Vertical: Services-Misc Health & Allied Services, NEC (SIC 8090)
NewGenIvf Group Ltd is an assisted reproductive services provider in Asia-Pacific, running clinics in Thailand, Cambodia and Kyrgyzstan that offer mainly IVF and fertility referral services. The company is in a fast transformation toward several business lines, and its liquidity position and shareholder dilution are important to watch; fiscal 2025 revenue was 4726433 USD, down from fiscal 2024, while the net income of 8763979 USD could be affected by unusual factors.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, NewGenIvf Group Ltd (NIVF) stock was 0.69 USD (−18.59% on the day), with market capitalisation 166.5 k USD, P/E 0.2 on diluted EPS of 3.04 USD over the last 12 months, beta 1.77, 52-week range 0.20–1,207.44 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 38.3
- weak (30–45)
- Bollinger (20, 2)
- -0.26 – 2.10
- in the lower half of the band · %B 0.40 · band width 257.0%
- SMA 50 / 200
- 2.21 / 46.38
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.35 / -0.46
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +57.3% | −1.1% | +58.4 pp | — |
| 3 months | −90.7% | −0.5% | −90.3 pp | — |
| 6 months | −98.6% | +4.4% | −103.0 pp | — |
| Year to date | −99.8% | +12.3% | −112.1 pp | — |
| 1 year | −99.9% | +13.5% | −113.5 pp | +17.9% |
| 3 years | −100.0% | +76.4% | −176.4 pp | −5.2% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 3-quarter history (min 98.1, median 1,808.4, max 4,667,796.6; quarters with earnings only).
Fiscal years
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4.1 m | 5.9 m | 5.1 m | 5.4 m | 4.7 m |
| Revenue YoY | unavailable | +44.3% | −13.6% | +5.8% | −13.0% |
| Net income | -533 | 458.7 k | 130.2 k | -524.6 k | 9.9 m |
| Net income YoY | unavailable | unavailable | −71.6% | −503.0% | unavailable |
| Diluted EPS | 0.00 | 4.72 | 13,019.30 | -4,408.76 | 3.04 |
| Diluted EPS YoY | unavailable | unavailable | +275,732.6% | −133.9% | unavailable |
| net % | -0.0% | 7.7% | 2.5% | -9.7% | 209.0% |
| Free cash flow | 1.4 m | 1.6 m | -1.8 m | -8.3 m | -11.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 758.6 k USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 26.0 m USD
- Total assets
- 32.7 m USD
- Debt / equity
- unavailable
- Current ratio
- 3.12x
- ROE
- unavailable
- ROA
- 54.4%
- FCF margin
- -234.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Revenue | 4.1 m | 5.9 m | 5.1 m | 5.4 m | 4.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Cost of revenue | 3.1 m | 4.4 m | 3.5 m | 3.6 m | 3.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Gross profit | 1.0 m | 1.5 m | 1.7 m | 1.8 m | 955.8 k | SEC (XBRL)· 31 Mar 2026verified |
| Operating income | 198.8 k | 398.7 k | 42.2 k | -1.2 m | -10.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Depreciation & amortisation | 166.7 k | 100.5 k | 31.2 k | 19.5 k | 188.1 k | SEC (XBRL)· 31 Mar 2026verified |
| EBITDA | 365.5 k ≈ | 499.2 k ≈ | 73.4 k ≈ | -1.1 m ≈ | -10.5 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Interest expense | — | — | 46.2 k | 765.2 k | 616.4 k | SEC (XBRL)· 31 Mar 2026verified |
| Pre-tax income | 156.2 k | 344.0 k | 108.4 k | -960.8 k | 9.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Income tax | 294.7 k | 208.1 k | — | -486.7 k | — | SEC (XBRL)· 22 Apr 2025verified |
| Net income | -533 | 458.7 k | 130.2 k | -524.6 k | 9.9 m | SEC (XBRL)· 31 Mar 2026verified |
| Diluted EPS | 0.00 | 4.72 | 13,019.30 | -4,408.76 | 3.04 | SEC (XBRL)· 31 Mar 2026verified |
| Weighted average diluted shares | 560.0 k | 28.8 k | 10 | 119 | 3.3 m | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Cash | 28.8 k | 27.6 k | 54.1 k | 457.7 k | 758.6 k | SEC (XBRL)· 31 Mar 2026verified |
| Receivables | — | 13.0 k | 9.4 k | 49.2 k | 166.5 k | SEC (XBRL)· 31 Mar 2026verified |
| Inventories | — | 46.9 k | 126.3 k | 80.8 k | 335.4 k | SEC (XBRL)· 31 Mar 2026verified |
| Current assets | — | 2.4 m | 2.5 m | 3.2 m | 7.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Property, plant & equipment, net | — | 122.7 k | 162.2 k | 273.1 k | 1.8 m | SEC (XBRL)· 31 Mar 2026verified |
| Intangibles (excl. goodwill) | — | — | — | — | 21.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Total assets | — | 2.9 m | 4.5 m | 3.6 m | 32.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Accounts payable | — | 104.7 k | 172.6 k | 1.3 m | 779.3 k | SEC (XBRL)· 31 Mar 2026verified |
| Current liabilities | — | 2.6 m | 1.1 m | 2.7 m | 2.4 m | SEC (XBRL)· 31 Mar 2026verified |
| Total liabilities | — | 2.8 m | 1.2 m | 5.1 m | 6.7 m | SEC (XBRL)· 31 Mar 2026verified |
| Equity | -914.9 k | 100.7 k | 3.2 m | -1.5 m | 26.0 m | SEC (XBRL)· 31 Mar 2026verified |
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.4 m | 1.7 m | -1.8 m | -8.3 m | -10.9 m | SEC (XBRL)· 31 Mar 2026verified |
| Capex | 16.6 k | 94.5 k | 69.8 k | 53.0 k | 135.0 k | SEC (XBRL)· 31 Mar 2026verified |
| Free cash flow | 1.4 m ≈ | 1.6 m ≈ | -1.8 m ≈ | -8.3 m ≈ | -11.1 m ≈ | SEC (XBRL)· 31 Mar 2026derived |
| Investing cash flow | -16.6 k | -94.5 k | -69.8 k | -53.0 k | -7.6 m | SEC (XBRL)· 31 Mar 2026verified |
| Financing cash flow | -1.5 m | -1.6 m | 1.9 m | 8.7 m | 19.0 m | SEC (XBRL)· 31 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 58.3% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 166.5 k USD
Key indicators
Coverage and freshness
Score by group
58% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 44.90 – 82.34 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E44.90 – 82.34 (Mid 65.44)6 companies used · median multiple 21.5x · quartiles 14.8x – 27.1xAGL, DVA, FMS, PGNY, SHC, VMD
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 58.3% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 209.0% | 100 (vs peers) | 11% |
| FCF conversion · Quality | -112.0% | 0 (on a fixed band) | 11% |
| Revenue CAGR 3Y · Growth | -7.4% | 0 (on a fixed band) | 14% |
| EPS CAGR 3Y · Growth | -13.6% | 0 (on a fixed band) | 14% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -17.4x | 0 (on a fixed band) | 11% |
| Current ratio · Balance sheet | 3.1x | 100 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | 0.2x | 100 (vs peers) | 18% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -6,642.9% | 0 (on a fixed band) | 14% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality50/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation56/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
NEWGENIVF GROUP LIMITED (NIVF). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 4.7 m USD in 2025; YoY growth -13.0%; net margin 209.0%; ROE 77.2%.
The estimated value range is 44.90–82.34 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 65.44 USD, the price of 0.69 USD leaves a potential of 9,356.1% (value / price − 1) and a margin of safety of 98.9% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 58.3% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 209.0%
- Current ratio: 3.1x
- P/E (TTM): 0.2x
- The price is below the estimated value range
What contradicts it
- FCF conversion: -112.0%
- Revenue CAGR 3Y: -7.4%
- EPS CAGR 3Y: -13.6%
- Interest coverage: -17.4x
- FCF yield: -6,642.9%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net debt / EBITDA, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Misc Health & Allied Services, NEC (SIC 8090) · same industry (4-digit SIC) · compared with 10 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| DVADavita Inc. | 12.1 bn | 14.2 | — | 6.5% | +6.5% | +61% / +90% |
| FMSFresenius Medical Care AG | 6.5 bn | 6.9 | 7.0% | 5.0% | +1.5% | −3% / +13% |
| SHCSotera Health Company | 4.7 bn | 27.3 | 27.0% | 14.1% | +5.7% | −6% / +20% |
| PGNYProgyny, Inc. | 2.3 bn | 32.7 | 16.2% | 6.0% | +10.4% | +14% / −12% |
| AGLagilon health, inc. | 1.6 bn | 16.5 | -29.7% | -1.5% | −2.1% | +491% / −64% |
| VMDViemed Healthcare, Inc. | 383.1 m | 26.5 | 11.0% | 5.0% | +20.5% | +46% / +30% |
| CCELCryo-Cell International, Inc. | 40.9 m | — | — | -6.2% | −1.3% | +18% / −5% |
| BRTXBiorestorative Therapies, Inc. | 38.5 m | — | -241.1% | -3,089.6% | −10.3% | +40% / −21% |
| MGRXMangoceuticals, Inc. | 4.5 m | — | -95.1% | -4,791.3% | −26.0% | −81% / −98% |
| NIVFNewgenivf Group Limited | 166.5 k | 0.2 | 77.2% | 209.0% | −13.0% | −100% / −100% |
| MCTACharming Medical Limited | — | — | -0.9% | -0.5% | −22.7% | unavailable / unavailable |
1- and 3-year price returns: for NIVF from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 5.00 Total return 622% · Per year 622% | 8.88 Total return 1,183% · Per year 1,183% | 13.43 Total return 1,841% · Per year 1,841% |
| 3 years | 3.97 Total return 473% · Per year 79% | 8.01 Total return 1,058% · Per year 126% | 13.43 Total return 1,841% · Per year 169% |
| 5 years | 3.15 Total return 355% · Per year 35% | 7.23 Total return 945% · Per year 60% | 13.43 Total return 1,841% · Per year 81% |
- Exit P/E± 2.00
- Net margin± 1.40
- Annual revenue growth± 1.27
- Annual dilution± 0.12
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 31 Mar 2026; since then the company filed 6-K (21 Oct 2026), 6-K (07 Oct 2026), 6-K (05 Oct 2026), 6-K (30 Sept 2026), 6-K (18 Aug 2026).
In brief
NewGenIvf Group Ltd is an assisted reproductive services provider in Asia-Pacific, running clinics in Thailand, Cambodia and Kyrgyzstan that offer mainly IVF and fertility referral services. The company is in a fast transformation toward several business lines, and its liquidity position and shareholder dilution are important to watch; fiscal 2025 revenue was 4726433 USD, down from fiscal 2024, while the net income of 8763979 USD could be affected by unusual factors.
SWOT
Strengths
- Nearly a decade of presence in the region, with a service portfolio covering IVF, egg donation and surrogacy referral across three countries.
- Exclusive or specially licensed technologies, including MicroSort, which the company regards as a first-mover advantage in Thailand and Cambodia.
- Multilingual staff and stage-based medical teams which, according to the company, support tailored services for foreign patients.
Weaknesses
- A limited operating history with the current platform, which makes it hard to predict future results and revenue growth.
- General and administrative expenses far exceed revenue, which eroded operating margins in fiscal 2025.
- Thin liquidity, with modest year-end cash and significant convertible debt, which raises questions about going-concern status.
Opportunities
- Growing fertility tourism in Asia-Pacific could bring new patients if complementary services such as transport and lodging are integrated.
- Investment in laboratories and technology acquisitions could widen the service range and could improve success rates.
- Partnerships with premium hospitality providers and academic institutions could grow the client base and research capacity.
Threats
- Better-established competitors with much larger resources could attract clients if they extend their services into the region.
- Travel restrictions and geopolitical tensions could reduce the number of foreign patients, particularly from China.
- Changes in regulation and clinic licensing could limit or delay the launch of new services.
Risks
- Going concern and liquidityhigh
The company states it cannot assure that it will have enough capital to bridge potential liquidity shortfalls, and adjustments to the accounts could be material if the going-concern basis is not appropriate.
- Shareholder dilutionhigh
Issuing shares through the equity line, warrants and convertible notes could reduce the stake of existing shareholders and could pressure the share price.
- Rapid strategic transformationmedium
Expansion into real estate, digital assets and mining is a major shift from the core business, and management has limited experience in these sectors, which could create costs and divert attention.
- SOL strategy and digital asset volatilitymedium
The plan to invest in the SOL token and stake it exposes the company to risks specific to the Solana network and to the volatility of digital assets, which could affect financial results.
- Dependence on clients from China and on travelmedium
A significant share of revenue comes from Chinese clients, and travel restrictions or a slowdown in the Chinese economy could materially affect operating results.
Investment thesis
What would need to be true (bull case)
- The company reported a net profit in fiscal 2025 after a loss in fiscal 2024, which, if it holds in later periods, could point to better operating efficiency.
- A first-mover position with MicroSort technology and access to advanced genetic technologies could offer a differentiation advantage against regional competitors.
- Long-term demand for assisted reproduction in Asia-Pacific, supported by demographic trends and public policy, could support revenue growth if the company expands its client base.
What would break the thesis
- Revenue fell in fiscal 2025 compared with fiscal 2024, and general and administrative expenses far exceeded revenue, which could make the net profit hard to sustain.
- Liquidity is limited, and financing through convertible notes and an equity line could keep diluting existing shareholders.
- The shift toward real estate, digital assets and mining could dilute the focus on the core business and create risks the company has not managed before.
What to watch
- Liquidity trend and use of the equity line and convertible notesQ1 2027
- Level of general and administrative expenses relative to revenue2027
- Number of foreign patients and revenue from clients in Chinanext 10-K
- Progress of the SOL investment plan and results of the new business lines2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 31 Mar 2026; since then the company filed 6-K (21 Oct 2026), 6-K (07 Oct 2026), 6-K (05 Oct 2026), 6-K (30 Sept 2026), 6-K (18 Aug 2026).
The business
NewGenIvf provides fertility treatments, mainly in vitro fertilization (IVF) including ICSI, embryo transfer and egg donation, plus fertility referral services in Kyrgyzstan. The company has three clinics, in Thailand, Cambodia and Kyrgyzstan, and its founders began as agents in 2011 before starting their own clinic in 2014. According to the annual report, about 82.6% of fiscal 2025 revenue came from IVF and 17.4% from referral services.
The company resulted from a business combination with A SPAC I Acquisition Corp., completed on April 3, 2024, which made Legacy NewGenIvf a wholly-owned subsidiary. The stated strategy includes full fertility services for fertility tourists in the region, investment in laboratories, and expansion through acquisitions and partnerships. In 2025 the company acquired the MicroSort technology and patents and machines from Nodexus Inc., which strengthen its gender selection and cell analysis offering.
Clinics run on a standardized model, with specialized medical teams by treatment stage and multilingual staff for patients from Asia-Pacific. The average cost of an IVF cycle, excluding medication, is around 7000 USD, which the company says makes its services competitive against the US market.
Segments
IVF and fertility treatments
IVF treatments, including ICSI, embryo transfer and egg donation, are the main segment, providing 82.6% of revenue in fiscal 2025 compared with 100% in fiscal 2024. Revenue is recognized when treatment is completed, marked by the written report confirming embryo implantation.
Fertility referral services
This segment, active in Kyrgyzstan, produced 17.4% of revenue in fiscal 2025. The company refers clients to independent agents for surrogacy services and receives a referral commission, which it says avoids the risks of the surrogacy business.
Market context
The assisted reproduction market in Asia-Pacific is described by the company as growing, supported by rising infertility, later age at first birth and policies such as China's Three-Child Policy of 2021. The market is highly regulated, and demand depends on clients from China whose travel can be affected by geopolitical tensions and travel restrictions in the region.
The lower cost of treatment compared with the US is a selling point, but new entrants or faster-than-expected development of competitors could put pressure on prices. Globally, the company sees growing demand for assisted reproduction as a long-term favourable trend.
Trends
- Rising infertility and demand for assisted reproductiontailwind
The company points to rising infertility, linked to later age at first birth and lifestyle factors, which supports long-term demand for assisted reproductive services.
- Government policies and recognition of same-sex marriagetailwind
Policies such as China's Three-Child Policy and legal recognition of same-sex marriage are seen by the company as factors that increase demand for treatments.
- Geopolitical and travel uncertaintyheadwind
The Middle East conflict and tensions at the Thailand-Cambodia border have disrupted flights and prompted travel advisories, which could reduce the number of foreign patients.
- Evolving regulationmixed
The regulatory framework for ARS clinics is changing in every jurisdiction where the company operates, and changes in licensing could affect the launch of new services and renewal of existing ones.
Competitive position
The company says no competitor had developed a similarly broad range of services in Asia-Pacific at the time of the report, but it acknowledges that many competitors are better established, have longer operating histories and far greater financial resources. As the field gains attention, more players could enter the market.
Competition can take the form of integrated services, superior clinical outcomes, larger networks of specialists, data reporting systems and investments in partners. The company did not name competitors with comparable data in the report, so its relative position in each market remains unclear.
- Fertility clinics and regional networks in Asia-Pacific
Local or regional competitors referred to generically in the report, with established networks and greater resources, and no US-listed ticker.
- Players in the Chinese assisted reproduction market
The company depends on clients from China, and domestic competitors may offer similar services to the same clientele, with no US listing.
- Fertility clinics in Thailand and Cambodia
Local competitors in these countries may offer similar treatments to fertility tourists, but the report gives no detail on their size.
- New entrants in genetic selection
The company warns that new entrants or rapid development of competing technologies could erode the first-mover advantage of MicroSort.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)21 Oct 2026
- Current report (foreign issuer)07 Oct 2026
- Current report (foreign issuer)07 Oct 2026
- Current report (foreign issuer)05 Oct 2026
- Current report (foreign issuer)30 Sept 2026
- Current report (foreign issuer)18 Aug 2026
- Current report (foreign issuer)17 Aug 2026
- Current report (foreign issuer)31 Jul 2026
- Current report (foreign issuer)30 Jul 2026
- Current report (foreign issuer)27 Jul 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / NewGenIvf Group Ltd · 31 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.